In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMarin raises $235.8mm in FOPO

Executive Summary

In its first public offering in five years, rare disease drug developer BioMarin Pharmaceutical Inc. raised $235.8mm through the sale of 6.5mm shares at $36.28. Since the company’s April 2007 $316mm FOPO, its Kuvan (sapropterin dihydrochloride) phenylketonuria treatment has received FDA approval and its Firdapse (amifampridine) was launched in the EU for Lambert-Eaton myasthenic syndrome (an autoimmune disease). BioMarin also continues to develop its pipeline for other orphan indications such as Pompe disease and Morquio A, both lysosomal storage disorders.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies